Eisai Company, Limited

Yasuo Ishibashi

Kazuhide Ashizawa

Sumio Watanabe

Yasuo Miyake

Naoki Asakawa

Fumio Kakimoto

Tadashi Sato

Masanori Kayano

Masahiro Kawahara

Kiyoshi Iwamoto

Ryoichi Machida

Yasuyuki Asai

Katsumi Onai

Kiyohiko Uchikawa

Isamu Hasegawa

Muneaki Matsuda

The present invention provides a preparation for injection containing a lipid A analog and a process for preparing the same. A preparation for injection prepared by dissolving a lipid A analog or a pharmacologically acceptable salt thereof in an alkaline aqueous solution, at an elevated temperature if necessary, and then adding a buffer thereto, and a process for preparing the same.

Injections containing lipid a analogues and process for the preparation thereof

A preparation containing a cephalosporin medicament is disclosed. The preparation comprises a cephalosporin derivative represented by the following formula: ##STR1## namely, 7.beta.-{2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-fluoromethoxyiminoacetami do}-3-{(E)-3-(carbamoylmethylethylmethylammonio) -1-propen-1-yl}-3-cephem-4-carboxylate or a pharmaceutically acceptable salt thereof salt, lactose, citric acid or a sodium salt thereof, and arginine or a hydrochloride thereof; or the cephalosporin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof, lactose, citric acid or a sodium salt thereof, and sodium chloride.

Injectable preparations containing cephalosporin medicament

A medical composition which contains a tissue Plasminogen Activator (tPA) in combination with meglumine or a salt thereof.

tPA-containing medical composition

Disclosed herein are 7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetamido]-3- (4-carbamoyl-1-quinuclidinio)methyl-3-cephem-4-carboxylate crystals comprising X-ray diffraction pattern possessing the characteristic diffraction intensity at the spacing d (unit: angstrom) shown in the following (i), (ii) or (iii):

Cephem derivative crystals

A composition containing a tissue Plasminogen Activator (tPA) which comprises a partial hydrolyzate of gelatin cross-linked to a diisocyanate as an essential ingredient; or alternatively a partial hydrolyzate of gelatin cross-linked to a diisocyanate and one or more of a basic amino acid or salt thereof. The composition enhances the solubility of the tPA in water, thereby making the tPA further available in the treatment of circulatory diseases caused by thrombi.

Composition containing tissue plasminogen activator

A cephalosporin having the formula ##STR1## is stabilized in an injection solution with lactose and/or sodium chloride.

Growing community of inventors

Gifu, Japan

Yasuo Ishibashi